Milestone Pharma slides after equity offering launch

** Milestone Pharmaceuticals' MIST shares down 24.2% to $1.94 premarket as co seeks equity raise

** Canada-based co commences stock-and-warrants offering

** It intends to use net offering proceeds to help fund clinical development and commercial launch of etripamil, its nasal spray to treat a type of heart condition called paroxysmal supraventricular tachycardia, among other purposes

** Co also announces U.S. FDA accepted for review its response to issues raised in Complete Response Letter for Cardamyst (etripamil)

** The health regulator has assigned a new Prescription Drug User Fee Act (PDUFA) target action date of Dec 13, 2025, co says

** On Mar 28, MIST shares plummeted 61% to close at 88 cents after FDA declined to approve Cardamyst and had called for an inspection of the facility that performs testing of the drug

** TD Cowen, Piper Sandler and Wells Fargo are jt bookrunners for the offering

** Co has ~53.46 mln shares outstanding and ~51 mln shares of public float, per LSEG data

** MIST shares on Thurs rose for 6th straight session, ending up nearly 7% at $2.56

** 2 analysts rate stock "buy", the other 2 rate "hold" and median PT is $4, according to latest LSEG data